“Global Defibrillators market set to grow to $15bn by 2024” says new Visiongain report

19 December 2018
Pharma

Visiongain has launched a new pharma report Global Defibrillators Market Forecast 2019-2029: External Defibrillators, Implantable Cardioverter Defibrillators, Transvenous ICD, Subcutaneous ICD, Single-Chamber ICD, Dual-Chamber ICD, Cardiac Resynchronization Therapy Defibrillators (CRT-D), Manual External Defibrillators, Automated External Defibrillators, Wearable Cardioverter Defibrillators.

Defibrillators are essential in improving the quality of life and overall well-being. The defibrillators industry is highly competitive and diverse with immense potential growth. Drivers for growth include availability of technologically advanced defibrillators, rapidly growing aging population leading to high risk of cardiovascular diseases, growing incidence of cardiovascular diseases and increasing awareness and training programmes related to defibrillators.

The lead analyst of the report commented "Growth in this market is set to be driven by the availability of technologically advanced defibrillators, rapidly growing aging population leading to high risk of cardiovascular diseases, growing incidence of cardiovascular diseases and increasing awareness and training programmes related to defibrillators. However, lack of awareness about sudden cardiac arrest, issues related to the use of defibrillator devices (external and implantable), and unfavourable healthcare reforms in the U.S. are some of the key factors restraining the growth of this market. In addition to this, increasing pricing pressure on market players and frequent product recalls pose major challenges to defibrillator manufacturers."

Leading companies featured in the report include Abbott Laboratories, Biotronik SE & Co. KG, Boston Scientific Corporation, Cardiac Science Corporation, LivaNova PLC, Medtronic PLC, Nihon Kohden Corporation, Phillips Healthcare, Physio Control Inc., Zoll Medical Corporation.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Global Bioreactors market set to grow to $1.6bn by 2024” says new Visiongain report

The bioreactors market is expected to grow over the forecast period owing to the increase in adoption of single use technologies and the growing popularity among pharmaceutical companies regarding the potential benefits of single-use bioreactors.

25 March 2019

Read

“Global Biosimilars and Follow-On Biologics Drugs market set to grow to $14bn by 2024” says new Visiongain report

Growth will be restrained in the biosimilar growth hormones submarket by steady uptake for branded therapies, high brand loyalty, as well as the launch of long-acting growth hormones.

21 March 2019

Read

“Global Asthma & COPD Therapies market set to grow to $46bn by 2024” says new Visiongain report

ecent studies and expert opinion suggest that the asthma and COPD market is more segregated than previously believed.

19 March 2019

Read

“Global Anaesthesia Drugs market set to grow to $11.8bn by 2024” says new Visiongain report

The intravenous route is the most commonly used route of administration owing to its high effectiveness during critical surgeries, its high adoption in hospitals, and availability of advanced intravenous drugs which cater the need of surgeons.

19 March 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever
WOOCS 2.2.1